Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
01:15pm, Wednesday, 12'th Mar 2025
BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.
CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the eff
Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)
06:02pm, Monday, 10'th Mar 2025
Biogen Inc. (NASDAQ:BIIB ) Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ET Company Participants Alisha Alaimo - President of North America Conference Call Participants Marc Goodma
The Nasdaq is Cratering But REGN, BIIB and CSGP Are Up Big Today
12:47pm, Monday, 10'th Mar 2025
If you're one of the over 4 Million Americans set to retire this year, you may want to pay attention.
Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)
06:29pm, Monday, 03'rd Mar 2025
Biogen Inc. (NASDAQ:BIIB ) TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ET Company Participants Chris Viehbacher - CEO Conference Call Participants Phil Nadeau - TD Cowen Phil Nad
EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug
07:55am, Friday, 28'th Feb 2025
European Union's human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen's Alzheimer's drug Leqembi, after it recommended its approval in November.
Biogen Stock Is Mutating Into a Value Play
07:43am, Thursday, 20'th Feb 2025
Biogen Inc. NASDAQ: BIIB has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology company
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
08:46am, Tuesday, 18'th Feb 2025
Stoke will receive $165 million upfront and may get up to $385 million in milestone payments.
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen's rare disease
Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
05:55am, Saturday, 15'th Feb 2025
Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing, mi
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
02:30pm, Thursday, 13'th Feb 2025
On Wednesday, Biogen Inc BIIB reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35.
Biogen Analysts Lower Their Forecasts After Q4 Results
09:03am, Thursday, 13'th Feb 2025
Biogen Inc BIIB reported better-than-expected earnings for its fourth quarter on Wednesday.
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
01:16pm, Wednesday, 12'th Feb 2025
BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
12:41pm, Wednesday, 12'th Feb 2025
Biogen Inc. (NASDAQ:BIIB ) Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Tim Power - Head of IR Chris Viehbacher - President and CEO Priya Singhal - Head of Develo
Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Wednesday, 12'th Feb 2025
The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima
